Having found that sequencing tdRT prior to αPD-1 drives tumor rejection through enhanced cross-presentation in the SLN and priming of antigen-specific CD8 + T cells (Fig. 4C, D), we next investigated whether the host response to sequenced tdRT→αPD-1 was dependent on the tumor-draining lymph node. The gene discussed is CD8A; the disease is neoplasm.